Search results
Showing 751 to 765 of 882 results for community guidance
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
More than 20,000 people benefitting from innovative migraine pills recommended by NICE
A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.
Interim methods guide for developing service guidance 2014 (PMG8)
This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
Discontinued Reference number: GID-TA10099
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.